Anti-Tumor Efficacy of Gene Vaccine Expressing PSMA

作     者：Xiao-ling YANG Jing LV Yue-hong ZHANG Bo NIU 

作者机构：Department of Laboratory Medicine Shanxi Bo'ai Hospital Taiyuan 030001 Shanxi Province China. Department of Biochemistry and Molecular Biology Shanxi Medical University Taiyuan 030001 Shanxi Province China. Biotechnology Research Laboratory Capital Institute of Pediatrics Beijing 100020 China. 

出 版 物：《Clinical oncology and cancer researeh》 (CLINICAL ONCOLOGY AND CANCER RESEARCH)

年 卷 期：2010年第7卷第6期

页      面：347-351页

核心收录：

学科分类：0710[理学-生物学] 1007[医学-药学(可授医学、理学学位)] 090602[农学-预防兽医学] 100705[医学-微生物与生化药学] 07[理学] 09[农学] 0906[农学-兽医学] 071005[理学-微生物学] 10[医学] 

主　　题：prostate cancer prostate-specific membrane antigen gene vaccine. 

摘      要：OBJECTIVE To observe anti-tumor effects of PVAX-PSMA gene vaccine. METHODS The PSMA gene was inserted into a mammalian expression vector, PVAX-1, to construct the DNA vaccine candidate, and was then used to vaccinate C57BL/6 mice. Animals vaccinated with PVAX-1 and NaC1 were used as controls. Anti-PSMA antibody was detected in sera of the animals. The proliferation and cytotoxicity of the spleen cells were observed. The immunized mice were inoculated with RM-1 cells. The mice were inoculated with RM-1 cells, and then the mice were immunized. The anti-tumor efficacy of the gene vaccine was evaluated by the ratio of tumor formation, tumor volume, tumor mass before and after gene vaccination and evaluated by survival rate of the immunized mice. RESULTS High level of anti-PSMA antibody was induced in the PVAX-PSMA group. The splenocytes from PVAX-PSMA group were stimulated to produce strong proliferation responses and significant cytotoxic T-cells （CTL） activity. After the mice were immunized with PVAX-PSMA gene, tumor occurrence was decreased, and the growth velocity of tumor was markedly reduced, resulting in prolonged tumor-free time （P 〈 0.05）. CONCLUSION PVAX-PSMA gene vaccine has significant anti- tumor effects and provides an experimental basis for primary prevention and immunotherapy of prostate cancer.